Researeh progress for tumor ache

Abstract

Abstract: Pain is a major symptom in patients suffering from cancer and also the most important factor which affects the quality of patients' lives.Cancer pain has unique mechanism from that of other kinds of pain.Recent years, there have established sorts of cancer pain models in rats and mice and modeled clinical pains caused by tumor intruding nerves or osseous metastasis, or pain of chemotherapy-induced peripheral neuropathy, and they have been used in evaluations of cancer pain treatment drugs.With the development of molecular biology technology and comprehend of pain mechanisms, relieve pain treatments in cell and gene levels as a new method have become an effective addition to traditional 3-stePanalgesic ladder.

Key words: cancer, pain, model, metastasis

CLC Number:

R441.1

JIANG Shou-yang, YUAN Sheng-tao. Researeh progress for tumor ache[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(12): 1332-1335.

References

1 Portenoy RK, Lesage P.Management of cancer pain[J].Lancet,1999;353:1695-700
2 吴勉华.癌性疼痛的中医药研究现状与对策[J].中国中医药信息杂志, 2005, 12:105-8
3 汤钊猷, 主编.现代肿瘤学[M].上海:上海医大出版社,1993:191-210
4 Wacnik PW, Kehl LJ, Trempe TM, Ramnaraine ML, Beitz AJ,Wilcox GL.Tumor implantation in mouse humerus evokes movement related hyperalgesia exceeding that evoked by intramuscular carrageenan[J].Pain, 2003;101:175-86
5 Clohisy DR, Mantyh PW.Bone cancer pain[J].Cancer, 2003;97:866-73
6 Cain DM, Wacnik PW, Turner M, Wendelschafer-Crabb G,Kennedy WR, Wilcox GL, et al.Functional interactions between tumor and peripheral nerve:changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain[J].J Neurosci, 2001;21:9367-76
7 Honore P, Rogers SD, Schwei MJ, Salak-Johnson JL, Luger NM, Sabino MC, et al.Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons[J].Neuroscience, 2000;98:585-98 Chin J Clin Pharmacol Ther 2006 Dec;11(12)
8 Lehre KP, Danbolt NC.The number of glutamate transporter subtype molecules at glutamatergic synapses:chemical and stereological quantification in young adult rat brain[J].J Neurosci,1998;18:8751-7
9 O' Connell JX, Nanthakumar SS, Nielsen GP, Rosenberg AE.Osteoid osteoma:the uniquely innervated bone tumor[J].Mod Pathol, 1998;11:175-80
10 Nozaki-Taguchi N, Chaplan SR, Higuera ES, Ajakwe RC,Yaksh TL.Vincristine-induced allodynia in the rat[J].Pain,2001;93:69-6
11 Polomano RC, Mannes AJ, Clark US, Bennett GJ.A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel[J].Pain, 2001;94:293-304
12 Boyle FM, Wheeler HR, Shenfield GM.Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate[J].J Neurooncol, 1999;41:107-16
13 Koning PD, Neijt JP, Jennekens FG, Gispen WH.Evaluation of cis-diamminedichloroplatinum (II)(cisplatin) neurotoxicity in rats[J].Toxicol Appl Pharmacol, 1987;98:81-7
14 Shimoyama M, Tanaka K, Hasue F, Shimoyama N.A mouse model of neuropathic cancer pain[J].Pain, 2002;99:167-74
15 张锐, 郝克强, 齐晓娟, 石庆宇, 李正民, 金华.S180 肉瘤损害小鼠坐骨神经动物模型的建立[J].中华实验外科杂志, 2005;22:763
16 Schwei MJ, Honore P, Rogers SD, Salak-Johnson JL, Finke MP, Ramnaraine ML, et al.Neurochemical and cellular reorganization of the spinal cord in amurine model of bone cancer pain[J].J Neurosci, 1999;19:10886-97
17 Wacnik PW, Eikmeier LJ, Ruggles TR, Ramnaraine ML,Walcheck BK, Beitz AJ, et al.Functional interactions between tumor and peripheral nerve:morphology, algogen identification,and behavioral characterization of a new murine model of cancer pain[J].J Neurosci, 2001;21:9355-66
18 Medhurst SJ, Walker K, BowesM, Kidd BL, GlattM, Muller M, et al.A rat model of bone cancer pain[J].Pain, 2002;96:129-40
19 Kim SH, Chung JM.An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat[J].Pain, 1992;50:355-63
20 Stein C,MillanMJ, Herz A.Unilateral inflammation of the hindpaw in rats as a model of prolonged noxious stimulation:alterations in behavior and nociceptive thresholds[J].Pharmacol Biochem Behav, 1988;31:451-5
21 Honore P, Rogers SD, Schwei MJ, Salak-Johnson JL, Luger NM,Sabino MC, et al.Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons[J].Nat Neurosci, 2000;98:585-95
22 Eaton MJ.Emerging cell and molecular strategies for the study and treatment of painful peripheral neuropathies[J].J Peripher Nerv Sy st, 2000;5:59-74
23 张可贤, 王志仪.癌痛治疗新概念-细胞镇痛, 基因治疗[J].四川肿瘤防治, 2005;18:203-5

[1]	YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan. Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
[2]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[3]	ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin. Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
[4]	FU Xiaoyu, KONG Deguang, LI Juanjuan. Treatment progress of triple positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
[5]	LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui. Advances in targeted therapy for HER2-positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
[6]	XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua. Research progress of biomarkers related to the efficacy of HER2 positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
[7]	CHEN Keyu, HUANG Yuan, WANG Xiaojia, ZHENG Yabing. Clinical application and research progress of antibody drugs conjugation in breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 898-909.
[8]	LI Mengxi, ZHANG Kejing, XIA Fan. Research progress in vaccine for breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 918-925.
[9]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[10]	HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong. Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831.
[11]	ZHANG Jinghui, WEI Haoliang, WANG Li, LI Jingkai, ZHANG Baolai, YANG Xiaolai. Effects of AMI-1 on the activity of pancreatic cancer cells in vitro by down-regulating PRMT5 expression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 601-608.
[12]	FU Ting, LI Fang, PAN Dayan, XIA Yuanyuan, ZHANG Qiuyuan. miR-718 from exosomes of lung cancer cells induces angiogenesis by targeting PTEN [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 624-632.
[13]	ZHAO Lu, LI Fuyong, WEN Binhong, LI Daowei. Effects of stains on hyperlipidemia and pain relieve of patients with chronic migraine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 671-675.
[14]	WANG Yan, ZHANG Jinhui, ZHAO Yongchen, LIU Hongxiang, LIU Yawei, MIAO Huanhuan, YANG Xincai. Sequoiaflavone inhibits stem cell properties such as proliferation and invasion of gastric cancer cells by down-regulating PI3K/AKT signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 508-513.
[15]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.